We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




Horiba Showcases New Generation Automated Hemostasis Analyzers at ISTH 2022

By LabMedica International staff writers
Posted on 07 Jul 2022
Print article
Image: The new generation Yumizen G800 and G1550 hemostasis analyzers (Photo courtesy of Horiba Medical)
Image: The new generation Yumizen G800 and G1550 hemostasis analyzers (Photo courtesy of Horiba Medical)

Horiba Medical (Kyoto, Japan) showcased the latest additions to its Yumizen G range of hemostasis analyzers and reagents at ISTH 2022 Congress - the premier event in the field of thrombosis and hemostasis - at London’s Excel from 9-13 July 2022.

At ISTH 2022, HORIBA introduced its new generation Yumizen G800 and G1550 hemostasis analyzers, as well as new ready-to-use reagents for frequently undertaken blood coagulation tests. With these introductions, HORIBA now offers a complete portfolio of hemostasis systems and an innovative reagent range suitable for all laboratory sizes and requirements. HORIBA’s comprehensive Yumizen G hemostasis product range fully supports high quality and cost-effective screening and assessment of bleeding disorders. The new generation of HORIBA Yumizen G800 and G1550 automated analyzers are designed for managing the coagulation, thrombophilia diagnostics and monitoring requirements of clinical laboratories with mid- to high-workloads. Supporting coagulant nephelometry, immuno-turbidimetric and chromogenic testing, these analyzers offer independent and integrated measurement channels.

The new hemostasis line also includes: liquid reagents for more than 80% of laboratory activity; pre-calibrated tests; continuous sample access and loading; as well as innovative management of reflex and additional tests. For urgent samples, it also offers eight STAT sample positions available at any time. Yumizen G systems use only one cuvette per test to avoid waste and overconsumption. The Yumizen G range has been designed to optimize costs, reduce expenses and reduce impact on environment.

Alongside the Yumizen G hemostasis range, HORIBA presented a variety of new specialty reagent additions, including dRVVT, protein S, protein C and Antithrombin screening and confirmation. HORIBA demonstrated its HELO laboratory automation platforms for hematology. Based on the combination of innovative and proven technologies, the HELO solution is capable of enhancing productivity and efficiency of any type of laboratory. At ISTH 2022, HORIBA also hosted a symposium with key opinion leaders in hemostasis from the UK and France presenting on the latest reagent evaluations and advancements in thrombophilia diagnosis.

“Leveraging our many years of expertise in hematology, we have meticulously designed all our Yumizen G systems to ensure that they are easy-to-use, efficient, robust and safe, along with a continuously expanding repertoire of tests,” said Bruno Pougault, Global Hemostasis Product Manager, HORIBA Medical.

Related Links:
Horiba Medical 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.